Literature DB >> 16413966

Elevated protein-bound levels of the lipid peroxidation product, 4-hydroxy-2-nonenal, in brain from persons with mild cognitive impairment.

D Allan Butterfield1, Tanea Reed, Marzia Perluigi, Carlo De Marco, Raffaella Coccia, Chiara Cini, Rukhsana Sultana.   

Abstract

Oxidative damage is a feature of many age-related neurodegenerative diseases, including Alzheimer's disease (AD). 4-Hydroxy-2-nonenal (HNE) is a highly reactive product of the free radical-mediated lipid peroxidation of unsaturated lipids, particularly arachidonic acid, in cellular membranes. In the present study we show for the first time in brain obtained at short postmortem intervals that the levels of HNE are elevated in mild cognitive impairment (MCI) hippocampus and inferior parietal lobules compared to those of control brain. Thus, increased levels of HNE in MCI brain implicate lipid peroxidation as an early event in AD pathophysiology and also suggest that the pharmacologic intervention to prevent lipid peroxidation at the MCI stage or earlier may be a promising therapeutic strategy to delay or prevent progression to AD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16413966     DOI: 10.1016/j.neulet.2005.12.017

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  95 in total

Review 1.  Functionalized nanosystems for targeted mitochondrial delivery.

Authors:  Shelley A Durazo; Uday B Kompella
Journal:  Mitochondrion       Date:  2011-11-23       Impact factor: 4.160

2.  Long-term high-dose atorvastatin decreases brain oxidative and nitrosative stress in a preclinical model of Alzheimer disease: a novel mechanism of action.

Authors:  Eugenio Barone; Giovanna Cenini; Fabio Di Domenico; Sarah Martin; Rukhsana Sultana; Cesare Mancuso; Michael Paul Murphy; Elizabeth Head; D Allan Butterfield
Journal:  Pharmacol Res       Date:  2010-12-27       Impact factor: 7.658

3.  Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease.

Authors:  M A Bradley; W R Markesbery; M A Lovell
Journal:  Free Radic Biol Med       Date:  2010-02-18       Impact factor: 7.376

Review 4.  Involvements of the lipid peroxidation product, HNE, in the pathogenesis and progression of Alzheimer's disease.

Authors:  D Allan Butterfield; Miranda L Bader Lange; Rukhsana Sultana
Journal:  Biochim Biophys Acta       Date:  2010-02-20

5.  Redox proteomics identification of 4-hydroxynonenal-modified brain proteins in Alzheimer's disease: Role of lipid peroxidation in Alzheimer's disease pathogenesis.

Authors:  Marzia Perluigi; Rukhsana Sultana; Giovanna Cenini; Fabio Di Domenico; Maurizio Memo; William M Pierce; Raffaella Coccia; D Allan Butterfield
Journal:  Proteomics Clin Appl       Date:  2009-06-01       Impact factor: 3.494

6.  Decreased levels of PSD95 and two associated proteins and increased levels of BCl2 and caspase 3 in hippocampus from subjects with amnestic mild cognitive impairment: Insights into their potential roles for loss of synapses and memory, accumulation of Abeta, and neurodegeneration in a prodromal stage of Alzheimer's disease.

Authors:  Rukhsana Sultana; William A Banks; D Allan Butterfield
Journal:  J Neurosci Res       Date:  2010-02-15       Impact factor: 4.164

Review 7.  Oxidatively modified, mitochondria-relevant brain proteins in subjects with Alzheimer disease and mild cognitive impairment.

Authors:  Rukhsana Sultana; D Allan Butterfield
Journal:  J Bioenerg Biomembr       Date:  2009-10       Impact factor: 2.945

8.  Oxidative stress in the progression of Alzheimer disease in the frontal cortex.

Authors:  Mubeen A Ansari; Stephen W Scheff
Journal:  J Neuropathol Exp Neurol       Date:  2010-02       Impact factor: 3.685

9.  Age-related loss of phospholipid asymmetry in APP(NLh)/APP(NLh) x PS-1(P264L)/PS-1(P264L) human double mutant knock-in mice: relevance to Alzheimer disease.

Authors:  Miranda L Bader Lange; Daret St Clair; William R Markesbery; Christa M Studzinski; M Paul Murphy; D Allan Butterfield
Journal:  Neurobiol Dis       Date:  2010-01-18       Impact factor: 5.996

Review 10.  Mitochondrial abnormalities in Alzheimer's disease: possible targets for therapeutic intervention.

Authors:  Diana F Silva; J Eva Selfridge; Jianghua Lu; Lezi E; Sandra M Cardoso; Russell H Swerdlow
Journal:  Adv Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.